Copenhagen-based hearing aid manufacturer Oticon, part of the Demant Group (CPH: DEMANT) on Wednesday introduced Oticon Zeal, a new in-the-ear hearing aid designed to eliminate the traditional trade-off between discreet design and full functionality, marking the creation of a new hearing aid category, NXT In-the-Ear.
Oticon Zeal integrates the company's BrainHearing technology to deliver clear, natural sound in all environments via the use of second-generation AI sound processing. The device offers same-day fitting, all-day battery life, and seamless connectivity, targeting users who value both aesthetics and advanced performance.
The new model is powered by encapsulation technology, similar to that used in pacemakers, enabling compact construction with durability and high moisture resistance. Its triple-function antenna is designed to ensure strong wireless connectivity while maintaining a deep, secure in-ear fit.
Oticon Zeal supports Google's Fast Pair feature for Android users and incorporates Auracast technology for enhanced audio streaming in public venues. The device also features seamless, stable connectivity with Apple products and can be controlled through the Oticon Companion app.
The rechargeable lithium-ion battery provides up to 20 hours of operation, with quick charging options offering four hours of use from just 15 minutes of charge.
Oticon positions Zeal as a complement to its existing Oticon Intent line, expanding its portfolio to better address diverse hearing needs across global markets.
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
OSR Holdings to acquire Korean non-invasive glucose monitor developer Woori IO
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux
Implantica receives positive FDA feedback on final RefluxStop PMA submission
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Shoulder Innovations expands I-Series portfolio with launch of InSet 70 Humeral Stem
GSK commits USD30bn to US R&D and manufacturing expansion
ArtPlayer Promotes Elderly Wellbeing with Digital Signage and Streaming Art in Finnish Care Homes
Implantica produces 10,000 RefluxStop units ahead of planned US launch